By Manas Mishra (Reuters) - Pfizer Inc (NYSE:PFE)'s $11.6 billion deal for migraine specialist Biohaven Pharmaceutical has kindled expectations on Wall Street that it may usher...
Intellia Therapeutics (NASDAQ:NTLA) reported Q1 EPS of ($1.96), $0.86 worse than the analyst estimate of ($1.10). Revenue for the quarter came in at $0 versus the consensus...
By David Randall NEW YORK (Reuters) - One year after her Ark Innovation ETF than doubled and made her a household name, star stock picker Cathie Wood is poised to join a small...
Last week, the Federal Reserve announced that it would maintain its accommodative monetary policy but begin tapering asset purchases. In other words, it is decreasing the massive...
The market had enough momentum left over from last week’s excellent performance to secure a fourth straight session of gains for two of the major indices. And now investors...
"The global health industry was worth $8.45 trillion in 2018 and global healthcare could reach over $10 trillion by 2022," according to PolicyAdvice a US insurance specialist. And...
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Strong Buy | Sell | Sell |
| Technical Indicators | Strong Buy | Strong Buy | Buy | Sell | Strong Sell |
| Summary | Strong Buy | Strong Buy | Strong Buy | Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 24.77 | 25.43 | 23.20 | +1.28 | +5.45% | 3.89M | NYSE | |||
| 13.13 | 13.42 | 12.84 | -0.16 | -1.20% | 2.38M | NASDAQ | |||
| 318.95 | 327.63 | 309.93 | -4.88 | -1.51% | 514.66K | NYSE | |||
| 44.16 | 45.64 | 43.41 | -0.73 | -1.63% | 2.46M | NYSE | |||
| 325.37 | 331.17 | 314.91 | +1.27 | +0.39% | 564.14K | NASDAQ | |||
| 9.96 | 10.06 | 9.92 | 0.00 | 0.00% | 198.82K | NYSE | |||
| 10.36 | 10.50 | 10.35 | +0.04 | +0.39% | 17.36K | NASDAQ | |||
| 22.72 | 22.76 | 22.72 | -0.26 | -1.13% | 4.38K | NYSE | |||
| 3.72 | 3.72 | 3.44 | -0.11 | -2.87% | 1.32K | NASDAQ | |||
| 25.33 | 25.50 | 25.33 | -0.02 | -0.08% | 3.83K | NYSE | |||
| 11.15 | 11.25 | 11.00 | 0.00 | 0.00% | 0.00 | NASDAQ | |||
| 9.44 | 9.52 | 9.32 | +0.04 | +0.43% | 9.52K | NYSE | |||
| 84.05 | 84.38 | 82.65 | +1.10 | +1.33% | 824.90K | NASDAQ | |||
| 4.82 | 4.82 | 4.74 | -0.03 | -0.62% | 214.00 | OTC Markets | |||
| 4.58 | 4.58 | 4.52 | +0.060 | +1.33% | 147.09K | NYSE |